Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia

与弗雷德·哈钦森癌症中心的多项目合作涵盖了膀胱癌生物标志物的发现，以及利用单细胞技术检测急性髓系白血病残留病灶的研究。

PLEASANTON, Calif.

加利福尼亚州普莱森顿

,

，

Oct. 7, 2026

2026年10月7日

/PRNewswire/ --

/美通社/ --

10x Genomics, Inc

10x Genomics 公司

. (Nasdaq:

.（纳斯达克：

TXG

TXG

), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with

），这家专注于加速科学进步和促进人类健康的生命科学科技领导者，今日宣布与

Fred Hutchinson Cancer Center

弗雷德·哈钦森癌症中心

(Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

（弗雷德·哈钦森癌症中心）作为美国领先的癌症研究机构之一，旨在推动单细胞和空间技术在实体瘤和血液系统恶性肿瘤中的应用。

The collaboration marks 10x's first clinical research initiative to extend beyond solid tumors into blood cancers, and builds on 10x's work to generate evidence for the clinical potential of its single cell and spatial products in oncology diagnostics.

此次合作标志着10x Genomics首次将临床研究计划从实体瘤扩展至血液癌症，并在此基础上进一步推进其单细胞和空间组学产品在肿瘤诊断中的临床潜力验证工作。

The first project intends to use 10x's Flex Apex and Xenium platforms, with plans to expand to the Atera platform, to investigate tumor samples from patients with advanced bladder cancer treated with antibody-drug conjugates, immune checkpoint inhibitors and other therapies. The goal is to correlate drug target expression and tumor microenvironment features with treatment response and clinical outcomes.

首个项目计划使用10x Genomics公司的Flex Apex和Xenium平台，并拟扩展至Atera平台，以研究接受抗体药物偶联物、免疫检查点抑制剂及其他疗法治疗的晚期膀胱癌患者的肿瘤样本。其目标是将药物靶点表达及肿瘤微环境特征与治疗反应和临床结局相关联。

From there, the 10x and Fred Hutch teams will explore biomarkers that could one day help inform therapy selection for oncologists and their patients..

在此基础上，10x公司与弗雷德·哈钦森癌症研究中心的团队将探索生物标志物，这些标志物有朝一日可能帮助肿瘤科医生及其患者制定治疗选择。

The second project intends to use the Flex Apex platform to investigate residual disease detection in acute myeloid leukemia (AML). Monitoring for residual leukemic cells after treatment is a critical part of guiding care for patients with AML, but today, it relies on a patchwork of separate technologies.

第二个项目旨在利用Flex Apex平台研究急性髓系白血病（AML）的残留病灶检测。治疗后对残留白血病细胞进行监测是指导AML患者治疗的关键环节，但目前这一过程依赖于多种分散的技术手段拼凑而成。

10x and Fred Hutch plan to investigate whether single cell analysis can improve and expand upon the current gold-standard methods..

10x Genomics 与弗雷德·哈钦森癌症中心计划研究单细胞分析是否能够改进并拓展当前的金标准方法。

Lawrence Fong

方志伟

, MD, will lead the collaboration for Fred Hutch. 'This project will help us better characterize the cellular and molecular responses to cancer treatments. We look forward to seeing how the results of this research could help guide treatment decisions for people with cancer,' said Fong, who is the scientific director of Fred Hutch's Integrated Immunotherapy Research Center and cares for patients with prostate, bladder and kidney cancers.

医学博士方将负责领导弗雷德·哈钦森癌症研究中心的合作项目。“该项目将帮助我们更好地表征对癌症治疗的细胞和分子反应。我们期待看到这项研究的结果如何为癌症患者的治疗决策提供指导，”方表示。他是弗雷德·哈钦森癌症研究中心综合免疫治疗研究中心的科学主任，并负责诊治前列腺癌、膀胱癌和肾癌患者。

Fong is also the Bezos Family Distinguished Scholar in Immunotherapy at Fred Hutch..

方博士也是弗雷德·哈钦森癌症中心的贝佐斯家族免疫疗法杰出学者。

'Across cancer care, we have more effective therapies than ever, and too little insight into which patient will actually benefit from which one,' said

“在癌症治疗领域，我们拥有比以往更有效的疗法，但对于哪些患者真正能从哪种疗法中获益，我们的了解却远远不够。”

Serge Saxonov

谢尔盖·萨克索诺夫

, Co-founder and CEO of 10x Genomics. 'Single cell and spatial biology let us look directly at the biology that drives treatment response, whether it's in a tumor or in the blood, and we believe that's the missing foundation for precision oncology. We're excited to work with Fred Hutch on this research.'.

10x Genomics联合创始人兼首席执行官表示：“单细胞和空间生物学让我们能够直接观察驱动治疗反应的生物学机制，无论是在肿瘤中还是在血液中，我们相信这正是精准肿瘤学所缺失的基石。我们很高兴能与弗雷德·哈钦森癌症研究中心合作开展这项研究。”

This collaboration builds on 10x's announced collaborations with leading hospitals and institutes, and, together with 10x's planned CLIA-certified laboratory, builds the scientific and operational foundation for potential future diagnostic applications in oncology and autoimmune disease. As part of this effort, 10x and Fred Hutch also plan to build a framework for future clinical reporting, defining how single cell and spatial features could support treatment planning in patients with cancer..

此次合作建立在10x Genomics此前宣布的与多家领先医院和研究机构的合作基础之上，并结合其计划建设的CLIA认证实验室，为未来在肿瘤学和自身免疫性疾病领域的潜在诊断应用奠定科学与运营基础。作为该工作的一部分，10x Genomics与弗雷德·哈钦森癌症中心还计划构建未来临床报告的框架，明确单细胞和空间特征如何支持癌症患者的治疗规划。

About 10x Genomics

关于 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

10x Genomics 是一家生命科学科技公司，致力于开发加速掌握生物学规律并推动人类健康的产品。我们的集成研究解决方案包括用于单细胞和空间生物学的仪器、耗材及软件，帮助学术与转化研究人员以及生物制药公司以契合生物学复杂性的分辨率和规模来理解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit .

我们的产品推动了肿瘤学、免疫学、神经科学等领域的突破性进展，催生了强有力的发现，正在改变世界对健康与疾病的认知。如需了解更多，请访问。

10xgenomics.com

10xgenomics.com

or connect with us on

或通过以下方式联系我们

LinkedIn

领英

,

，

X

X

,

，

Facebook

脸书

,

，

Bluesky

蓝空

or

或者

YouTube

YouTube

.

。

Forward Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections.

本新闻稿包含根据1933年《证券法》（经修订）第27A条和1934年《证券交易法》（经修订）第21E条所定义的“前瞻性陈述”，这些陈述受上述条款所设立的“安全港”规则保护。

All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'see,' 'estimate,' 'predict,' 'potential,' 'would,' 'likely,' 'seek' or 'continue' or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

本新闻稿中包含的所有陈述，除历史事实陈述外，均可能构成前瞻性陈述。前瞻性陈述通常可以通过使用诸如“可能”、“也许”、“将”、“应该”、“预期”、“计划”、“预计”、“能够”、“打算”、“目标”、“规划”、“考虑”、“相信”、“看到”、“估计”、“预测”、“潜在”、“会”、“很可能”、“寻求”或“继续”等前瞻性术语，或这些术语的否定形式、变体或类似术语来识别，但未出现这些词语并不意味着某项陈述不属于前瞻性陈述。

These forward-looking statements include statements regarding 10x Genomics' products, services and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.

这些前瞻性陈述包括有关10x Genomics的产品、服务和合作的陈述。这些陈述基于管理层当前的预期、预测、信念、假设以及目前可获得的信息。由于多种因素，实际结果可能与这些陈述存在重大差异，因此不应将这些陈述视为代表10x Genomics, Inc.在本新闻稿发布日期之后任何日期的观点。

10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s fi.

10x Genomics, Inc. 声明，除非法律另有要求，否则不承担任何义务以更新任何前瞻性陈述，以反映10x Genomics预期的任何变化，或此类陈述所基于的事件、条件或情况的任何变化。可能影响10x Genomics, Inc.的重大风险和不确定性包括...

Contacts

联系人

Investors:

投资者：

[email protected]

[email protected]

Media:

媒体：

[email protected]

[email protected]

SOURCE 10x Genomics, Inc.

来源：10x Genomics, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示